ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CNSY / insiders
GUTS (34) SINT (33) ICU (31) CTSO (22) ⌘ Pro Terminal →

Cerenome Inc. (CNSY) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.71 +0.59% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.71

Cerenome Inc. (CNSY) carries a Roarable Rating of E (Strong Sell) with 25/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $12.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CNSY Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CNSY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Cerenome Inc. (NASDAQ: CNSY) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $1.71 (+0.59% 1D, market cap $12.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CNSY ranks #933 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CNSY compare to GUTS and SINT in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), CNSY carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GUTS (Fractyl Health Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $13.0M) and SINT (SiNtx Technologies Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $12.8M). Among the 5-stock peer group, CNSY leads on earnings multiple (N/A) while CNSY leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CNSY?
▼

Per CNSY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001095981), Cerenome Inc. generated $5.2M in revenue (-10.5% YoY), -$22.4M in net income, and -$20.8M in free cash flow against $16.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.71 (-0.08%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (25/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510025
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (6)Whales (3)SEC (5)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-14.6% Base Target
$20 Bull$1 Base$1 Bear
📬 FREE CNSY RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CNSY)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (25/100 Composite)
🔍 WHY CNSY SCORES 25/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+8/20 pts (32% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 43.6 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Cash Engine Quality+6/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
33
Grade E$1.74-3.4% Next Q
Q2 (-2Q)
30
Grade E$1.68-1.2% Next Q
Q3 (-1Q)
28
Grade E$1.66+3% Next Q
Current
25
Grade E$1.71-10.7% Hist 90D α
Trajectory: E (33) → E (25)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CNSY Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CNSY currently carries a cautious 25/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.07) and Max Pain ($1.80) forces dealer call-delta covering toward $19.95.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CNSY• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CNSY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 25%NO 75%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

CNSY Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (CNSY)

No recent open-market Form 4 cluster sales or emergency dumps flagged on CNSY. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CNSY)

  • ✓Walkthrough of CNSY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CNSY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -72.86%⚡ TESTING RESISTANCE
2026-11-03O $1.74H $1.74L $1.70C $1.71VOL 47.8K
RES: $1.73SUP: $0.61SMA50: $2.07SMA200: $4.57
$11.88$9.06$6.25$3.43$0.62RES $1.73SUP $0.61$1.712026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CNSY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CNSY Butterfly Map → + Track CNSY →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -10.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CNSY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CNSY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CNSY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CNSY)

Health Care Rank #933 of 1015 ⚔️ GUTS vs CNSY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CNSY vs. GUTS, SINT, ICU, CTSO)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Cerenome Inc. (CNSY) ranks #933 by composite RQD confidence (25/100, grade E) and #866 by equity capitalization ($12.9M). Within this direct 5-issuer industry benchmark cohort, CNSY leads on earnings valuation at N/A trailing P/E, while CNSY leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GUTS currently holds the highest overall quantitative score in the immediate peer group at 34/100 (E) compared with CNSY at 25/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CNSY ACTIVE
Cerenome Inc.
E 25/100 — — -35.0% +0.59% $12.9M Benchmark Subject
GUTS
Fractyl Health Inc.
E 34/100 — — -35.0% -3.47% $13.0M /guts-vs-cnsy →
SINT
SiNtx Technologies Inc.
E 33/100 — 45.3% -35.0% +0.59% $12.8M /sint-vs-cnsy →
ICU
SeaStar Medical Holding Corporation
E 31/100 — 95.7% -35.0% -2.23% $11.8M /icu-vs-cnsy →
CTSO
Cytosorbents Corporation
E 22/100 — 71.5% -35.0% -9.25% $14.3M /ctso-vs-cnsy →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001095981 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cerenome Inc. (CNSY) reported GAAP revenue of $5.2M (-10.5% vs. FY2024 revenue of $5.8M , and +6.1% cumulative change since FY2023) , GAAP net income of -$22.4M, operating cash flow of -$20.8M, and free cash flow of -$20.8M (-94.8% YoY). On the balance sheet, CNSY closed FY2025 with $16.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $5.2M -$22.4M -$20.8M -$20.8M $16.3M —
FY2024 (FY) 2024-12-31 $5.8M -$13.0M -$10.6M -$10.7M $6.6M —
FY2023 (FY) 2023-12-31 $4.9M -$13.3M -$12.9M -$12.9M — —

3. CNSY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CNSY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Cerenome Inc. (NASDAQ: CNSY) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $1.71 (+0.59% 1D, market cap $12.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CNSY ranks #933 in composite RQD confidence.

How does CNSY compare to GUTS and SINT in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), CNSY carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GUTS (Fractyl Health Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $13.0M) and SINT (SiNtx Technologies Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $12.8M). Among the 5-stock peer group, CNSY leads on earnings multiple (N/A) while CNSY leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CNSY?

Per CNSY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001095981), Cerenome Inc. generated $5.2M in revenue (-10.5% YoY), -$22.4M in net income, and -$20.8M in free cash flow against $16.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CNSY trading relative to its 50-day, 200-day, and 52-week technical levels?

CNSY last traded at $1.71 (+0.59% on volume of 51,962 shares), positioning the stock -17.39% below its 50-day simple moving average ($2.07) and -62.58% below its 200-day simple moving average ($4.57). Across its 52-week range of $1.49 to $19.00, CNSY sits at the 1.3% percentile with a 14-day RSI of 43.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.50 to $1.92).

Direct Sub-Reports: CNSY RQD Cockpit CNSY 12M Forecast CNSY Earnings & Move CNSY Dividends & DRIP CNSY Insiders & 13F CNSY Whale Options CNSY Profit Sankey CNSY News & Why
ROARABLE RATING BRIEF • RQD 25/100 (E) ✓ SEC XBRL & RQD VERIFIED

CNSY — Cerenome Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Cerenome Inc. (CNSY) earns a live Roarable RQD composite score of 25/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.71 (+0.59% 1D, market capitalization $12.9M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Cerenome Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry. Its market capitalization is $0.0B. The news wire describes the company as engaged in clinical-stage oncology development, including a Phase 2 ReSPECT-GBM trial of REYOBIQ™ in recurrent glioblastoma. The revenue base is $5.2M in FY 2025, but the source does not specify the product sales mix or customer base.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Cerenome Inc. (CNSY) reported $5.2M in annual revenue (up from $5.8M in FY2024, -10.5% YoY) and -$22.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($4.9M revenue, -$13.3M net income) through FY2025, CNSY scaled operating cash flow to -$20.8M and free cash flow to -$20.8M, backed by $16.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 25/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.49 – $19.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— Sector-level context is limited to the classification of Health Care and Medical/Dental Instruments. No upstream or downstream dependencies, sector correlations, or second-order bottlenecks are identified in the source data.

  • Key Question #1: Can CNSY sustain or expand its -60.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $5.2M and free cash flow of -$20.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CNSY's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CNSY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cerenome Inc. (CNSY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CNSY Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CNSY Bull vs. Bear Conversation Board — What's Your Call at $1.71?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CNSY 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CNSY:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $1.95 (+14.7%)
📌 Pinned Debate

Per the news wire, enrollment has been completed in the Phase 2 ReSPECT-GBM trial of REYOBIQ™ in recurrent glioblastoma, a potential ca

Per the news wire, enrollment has been completed in the Phase 2 ReSPECT-GBM trial of REYOBIQ™ in recurrent glioblastoma, a potential catalyst.. When you look under the hood at CNSY, Fundamental Cash Engine is 6/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $19.00. My 12M target is $1.95.

VolSurface_Trader 🐂 BULL

Both sides have a point here — CNSY's 5/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $1.38 (-18.8%)
Spot @ $1.70

Per the RQD rating, the company scores 27/100 (grade E) with a -35% ROIC, 0% FCF yield, and a Piotroski F-Score of 2/9.

Careful chasing CNSY at $1.70. Per the RQD rating, the company scores 27/100 (grade E) with a -35% ROIC, 0% FCF yield, and a Piotroski F-Score of 2/9.. Gross margin is 0.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.38 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%